The Pharmacology of Visual Hallucinations in Synucleinopathies
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Synucleinopathies include Parkinson’s disease and Dementia with Lewy Bodies, where visual hallucina-tions (VH) are so frequent to lead to the conclusions that if hallucinations do not appear during the dis-ease course, diagnosis should be challenged. VH may be early and simple and late and complex, includ-ing hallucinatory states which represent an unmet need for treatment. Our review analyses old and re-cent hypotheses on the mechanisms of VH and discusses a number of drugs involved in production and suppression the VH, in order to complete the hypothesis of mechanisms. Recent models of VH are cen-tered on decoupling of the Default Mode Network (DMN), which is released in these disorders from the fronto-parietal control and from salience networks, resulting in perception of priors stored in uncon-scious memory. The release of DMN supposedly releases the intrinsic narrative of DMN. The thalamus represents a powerful control relay according to recent theories on “cognitive thalamus”. The networks involved imply practically all relevant neurotransmitters, including glutamic acid, Gamma-Aminobutyric Acid (GABA), dopamine, serotonin, acetylcholine. Actually, evidence-based medicine can only rely on clozapine, an old drug very effective but burdened by several side effects. According to the models, serotonergic, glutamatergic, GABAergic and dopaminergic pathways should be investigated in order to develop possible new treatment drugs. According to a possible model of thalamic dysfunction, also drug acting on calcium channels might find a role. Our review analyses also the agonist and antagonist drugs and reports on drugs inducing hallucinations as side effects, which should be taken into account when managing hallucinating disorders in these patients, who are also carriers of many comorbidities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The free-energy principle: a unified brain theory?
Friston, K. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2787 · Cited by 8,120 · cited 1×
“The model posits that alterations of the network balance affect the brain computational processes involved in predictive coding (Friston, 2010; Sterzer et al., 2018).”
BackgroundWhatever next? Predictive brains, situated agents, and the future of cognitive science
Clark, A. (2013) · Behavioral and Brain Sciences · doi:10.1017/s0140525x12000477 · Cited by 5,924 · cited 1×
“According to the model, VH arise when the overall prevalence of priors (i.e., the inner prior knowledge of likely candidates that match a given sensory input) over perceptions generates new percepts that are not based on matching stimuli (Clark, 2013).”
BackgroundDiagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Self-citationThe brain's default mode network
Raichle, M. E. (2015) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071013-014030 · Cited by 3,904
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568 · cited 6×
“…glutamate receptors (mGluR 1–8 receptors) are classified in three groups depending on the binding specificity, ionic modulation, and conductance properties: group 1 (mGluR1 and mGluR5), group 2 (mGluR2 and mGluR3), and group 3 (mGluR4, mGluR6, mGluR7, and mGluR8) (Traynelis et al., 2010).”
BackgroundInfluentialAcetylcholinesterase Inhibitors: Pharmacology and Toxicology
Colovic, M. B., Krstic, D. Z., Lazarevic-Pasti, T. D., Bondzic, A. M., & Vasic, V. M. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030006 · Cited by 2,611
Fick, D. M., Cooper, J. W., Wade, W. E., Waller, J. L., Maclean, J. R., & Beers, M. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.22.2716 · Cited by 2,389
Cortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
The role of the posterior cingulate cortex in cognition and disease
Leech, R., & Sharp, D. J. (2014) · Brain · doi:10.1093/brain/awt162 · Cited by 2,247 · cited 2×
“A critical player in the production of the network unbalance is the PCC (Figure 3), a region belonging to the DMN (Leech and Sharp, 2014) that exhibits transitional patterns of connectivity with TPNs.”
BackgroundCholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
The neural bases of momentary lapses in attention
Weissman, D. H., Roberts, K. C., Visscher, K. M., & Woldorff, M. G. (2006) · Nature Neuroscience · doi:10.1038/nn1727 · Cited by 1,566
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Nicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System
Dani, J. A., & Bertrand, D. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105214 · Cited by 1,197
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Dopamine and the regulation of cognition and attention
Nieoullon, A. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00011-4 · Cited by 1,131 · cited 2×
“Changes in the striatal dopamine levels have been found to correlate with the DMN activation (Tomasi et al., 2009) and the modulation of the attention pathways (Nieoullon, 2002).”
BackgroundMiyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Neuronal nicotinic receptors: from structure to pathology
Gotti, C., & Clementi, F. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.09.006 · Cited by 970
The Predictive Coding Account of Psychosis
Sterzer, P., Adams, R. A., Fletcher, P., Frith, C., Lawrie, S. M., Muckli, L., Petrovic, P., Uhlhaas, P., Voss, M., & Corlett, P. R. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.05.015 · Cited by 941
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Sonuga-Barke, E. J. S., & Castellanos, F. X. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.02.005 · Cited by 890
Brain nicotinic acetylcholine receptors: native subtypes and their relevance
Gotti, C., Zoli, M., & Clementi, F. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.07.004 · Cited by 882
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859
Thalamus plays a central role in ongoing cortical functioning
Sherman, S. M. (2016) · Nature Neuroscience · doi:10.1038/nn.4269 · Cited by 809
Waldhoer, M., Bartlett, S. E., & Whistler, J. L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073940 · Cited by 740
Metabotropic glutamate receptors as novel targets for anxiety and stress disorders
Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1630 · Cited by 607
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13282-7 · Cited by 587
Visual dysfunction in Parkinson’s disease
Weil, R. S., Schrag, A. E., Warren, J. D., Crutch, S. J., Lees, A. J., & Morris, H. R. (2016) · Brain · doi:10.1093/brain/aww175 · Cited by 481
The pharmacology of psilocybin
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002) · Addiction Biology · doi:10.1080/1355621021000005937 · Cited by 465 · cited 1×
“Psilocybin is an alkaloid tryptamine found in mushrooms like the Psilocybe mexicana (Passie, 2002).”
BackgroundPalhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
The ABC of GABA receptors: a brief review
Chebib, M., & Johnston, G. A. R. (1999) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.1999.03151.x · Cited by 436 · cited 2×
“GABA-A and GABA-C receptors are ionotropic, whereas GABA-B is metabotropic.”
BackgroundMcKenna, D. J., Towers, G. H. N., & Abbott, F. (1984) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(84)90003-5 · Cited by 398
Untangling the complexity of opioid receptor function
Valentino, R. J., & Volkow, N. D. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0225-3 · Cited by 383
Finding the self by losing the self: neural correlates of ego-dissolution under psilocybin
Lebedev, A. V., Lövdén, M., Rosenthal, G., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015) · Human Brain Mapping · doi:10.1002/hbm.22833 · Cited by 339
Structure and subunit composition of GABAA receptors
Sieghart, W., Fuchs, K., Tretter, V, Ebert, V, Jechlinger, M., Höger, H., & Adamiker, D. (1999) · Neurochemistry International · doi:10.1016/s0197-0186(99)00045-5 · Cited by 306
Antidepressants for agitation and psychosis in dementia
Seitz, D. P., Adunuri, N., Gill, S. S., Gruneir, A., Herrmann, N., & Rochon, P. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008191.pub2 · Cited by 304
Riba, J., Rodríguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M., Callaway, J. C., & Barbanoj, M. J. (2001) · Psychopharmacology · doi:10.1007/s002130000606 · Cited by 303
Effective connectivity changes in LSD-induced altered states of consciousness in humans
Preller, K. H., Razi, A., Zeidman, P., Stämpfli, P., Friston, K. J., & Vollenweider, F. X. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815129116 · Cited by 292
McCormick, D. A., & Wang, Z. (1991) · The Journal of Physiology · doi:10.1113/jphysiol.1991.sp018791 · Cited by 285
Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis
Carhart-Harris, R. L., Leech, R., Erritzoe, D., Williams, T. M., Stone, J. M., Evans, J., Sharp, D. J., Feilding, A., Wise, R. G., & Nutt, D. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs117 · Cited by 256
Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant
Riba, J., Romero, S., Grasa, E., Mena, E., Carrió, I., & Barbanoj, M. J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0358-7 · Cited by 241
Ayahuasca: pharmacology, neuroscience and therapeutic potential
Domínguez-Clavé, E., Soler, J., Elices, M., Pascual, J. C., Álvarez, E., de la Fuente Revenga, M., Friedlander, P., Feilding, A., & Riba, J. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.03.002 · Cited by 226
Driesen, N. R., McCarthy, G., Bhagwagar, Z., Bloch, M., Calhoun, V, D'Souza, D. C., Gueorguieva, R., He, G., Ramachandran, R., Suckow, R. F., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.194 · Cited by 224
Zhang, W., Yamada, M., Gomeza, J., Basile, A. S., & Wess, J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06347.2002 · Cited by 224
Bonhomme, V., Vanhaudenhuyse, A., Demertzi, A., Bruno, M.-A., Jaquet, O., Bahri, M. A., Plenevaux, A., Boly, M., Boveroux, P., Soddu, A., et al. (2016) · Anesthesiology · doi:10.1097/aln.0000000000001275 · Cited by 207
Calcium signalling and psychiatric disease: bipolar disorder and schizophrenia
Berridge, M. J. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1806-z · Cited by 181
Tomasi, D., Volkow, N. D., Wang, R., Telang, F., Wang, G.-J., Chang, L., Ernst, T., & Fowler, J. S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006102 · Cited by 154
Huot, P., Johnston, T. H., Darr, T., Hazrati, L., Visanji, N. P., Pires, D., Brotchie, J. M., & Fox, S. H. (2010) · Movement Disorders · doi:10.1002/mds.23083 · Cited by 153
Niesters, M., Khalili-Mahani, N., Martini, C., Aarts, L., van Gerven, J., van Buchem, M. A., Dahan, A., & Rombouts, S. (2012) · Anesthesiology · doi:10.1097/aln.0b013e31826a0db3 · Cited by 147
Kessler, R. M., Woodward, N. D., Riccardi, P., Li, R., Ansari, M. S., Anderson, S., Dawant, B., Zald, D., & Meltzer, H. Y. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.12.029 · Cited by 136
Presynaptic serotonin 2A receptors modulate thalamocortical plasticity and associative learning
Barre, A., Berthoux, C., De Bundel, D., Valjent, E., Bockaert, J., Marin, P., & Bécamel, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525586113 · Cited by 135
De Gregorio, D., Posa, L., Ochoa-Sanchez, R., McLaughlin, R., Maione, S., Comai, S., & Gobbi, G. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.022 · Cited by 110
Developmental regulation of the NMDA receptor subunits, NR3A and NR1, in human prefrontal cortex
Henson, M. A., Roberts, A. C., Salimi, K., Vadlamudi, S., Hamer, R. M., Gilmore, J. H., Jarskog, L. F., & Philpot, B. D. (2008) · Cerebral Cortex · doi:10.1093/cercor/bhn017 · Cited by 110
Shine, J. M., Muller, A. J., O’Callaghan, C., Hornberger, M., Halliday, G. M., & Lewis, S. J. (2015) · npj Parkinson's Disease · doi:10.1038/npjparkd.2015.3 · Cited by 106
Reduced occipital GABA in Parkinson disease with visual hallucinations
Firbank, M. J., Parikh, J., Murphy, N., Killen, A., Allan, C. L., Collerton, D., Blamire, A. M., & Taylor, J.-P. (2018) · Neurology · doi:10.1212/wnl.0000000000006007 · Cited by 103
Visual plus nonvisual hallucinations in Parkinson's disease: Development and evolution over 10 years
Goetz, C. G., Stebbins, G. T., & Ouyang, B. (2011) · Movement Disorders · doi:10.1002/mds.23835 · Cited by 91
Inserra, A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00330 · Cited by 91 · cited 1×
“DMT can also bind and activate the stress-responsive sigma 1 receptors that are involved in neuroplasticity and neuromodulatory functions (Inserra, 2018).”
BackgroundThe muscarinic system, cognition and schizophrenia
Carruthers, S. P., Gurvich, C. T., & Rossell, S. L. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.011 · Cited by 90
Onofrj, M., Thomas, A., & Bonanni, L. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.12.1731 · Cited by 41
Self-citationHallucination induced by paroxetine discontinuation in patients with major depressive disorders
Yasui‐Furukori, N., & Kaneko, S. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2011.02211.x · Cited by 13
Cited by
Understanding visual hallucinations: A new synthesis
Collerton, D., Barnes, J., Diederich, N. J., Dudley, R., ffytche, D., Friston, K., Goetz, C. G., Goldman, J. G., Jardri, R., Kulisevsky, J., et al. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105208 · Cited by 83
“Pharmacological (e.g. Russo et al., 2019) or environmental (e.g.”
BackgroundSelf-citationParkinson disease psychosis: from phenomenology to neurobiological mechanisms
Pagonabarraga, J., Bejr-Kasem, H., Martinez-Horta, S., & Kulisevsky, J. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-023-00918-8 · Cited by 69
Onofrj, M., Russo, M., Delli Pizzi, S., De Gregorio, D., Inserra, A., Gobbi, G., & Sensi, S. L. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02691-0 · Cited by 43
“Similar changes have also been linked to mood disorders and, interestingly, VH onset [36].”
BackgroundResultInfluentialSelf-citationZarkali, A., McColgan, P., Leyland, L. A., Lees, A. J., & Weil, R. S. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326630 · Cited by 32
Visual hallucinations in Parkinson’s disease: spotlight on central cholinergic dysfunction
Ignatavicius, A., Matar, E., & Lewis, S. J. G. (2025) · Brain · doi:10.1093/brain/awae289 · Cited by 32
Metadata
- Authors
- Russo, M., Carrarini, C., Dono, F., Rispoli, M. G., Di Pietro, M., Di Stefano, V., Ferri, L., Bonanni, L., Sensi, S. L., & Onofrj, M.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2019-12-09
- Volume
- 10
- Pages
- 1379-1379
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2996042692
- Cited by
- 55
- References
- 64
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.